[미국특허]
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12M-003/00
C12M-001/12
출원번호
US-0843097
(2010-07-26)
등록번호
US-8796023
(2014-08-05)
발명자
/ 주소
Reches, Meital
Gazit, Ehud
출원인 / 주소
Ramot at Tel-Aviv University Ltd.
인용정보
피인용 횟수 :
8인용 특허 :
69
초록▼
A nanostructure composed of a plurality of peptides, each peptide containing at least one aromatic amino acid, whereby one or more of these peptides is end-capping modified, is disclosed. The nanostructure can take a tubular, fibrillar, planar or spherical shape, and can encapsulate, entrap or be co
A nanostructure composed of a plurality of peptides, each peptide containing at least one aromatic amino acid, whereby one or more of these peptides is end-capping modified, is disclosed. The nanostructure can take a tubular, fibrillar, planar or spherical shape, and can encapsulate, entrap or be coated by other materials. Methods of preparing the nanostructure, and devices and methods utilizing same are also disclosed.
대표청구항▼
1. An artificial tissue comprising viable cells incorporated throughout a porous biocompatible matrix composed of at least one nanostructure, said at least one nanostructure being selected from the group consisting of a tubular nanostructure and a fibrillar nanostructure, and comprising a plurality
1. An artificial tissue comprising viable cells incorporated throughout a porous biocompatible matrix composed of at least one nanostructure, said at least one nanostructure being selected from the group consisting of a tubular nanostructure and a fibrillar nanostructure, and comprising a plurality of aromatic homodipeptides, wherein at least one of said homodipeptides is an end-capping modified peptide. 2. The artificial tissue of claim 1, wherein said end capping moiety is an aromatic moiety and the nanostructure is a fibrillar nanostructure. 3. The artificial tissue of claim 2, wherein said aromatic end capping moiety is selected from the group consisting of 9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz). 4. The artificial tissue of claim 1, wherein said end-capping moiety is a non-aromatic moiety and the nanostructure is a tubular nanostructure. 5. The artificial tissue of claim 4, wherein said non-aromatic end capping moiety is selected from the group consisting of acetyl and tert-butoxycarbonyl (Boc). 6. The artificial tissue of claim 1, wherein said homodipeptide is phenylalanine-phenylalanine dipeptide. 7. The artificial tissue of claim 1, wherein said homodipeptide is selected from the group consisting of naphthylalanine-naphthylalanine dipeptide, (pentafluro-phenylalanine)-(pentafluro-phenylalanine) dipeptide, (iodo-phenylalanine)-(iodo-phenylalanine) dipeptide, (4-phenyl phenylalanine)-(4-phenyl phenylalanine) dipeptide and (p-nitro-phenylalanine)-(p-nitro-phenylalanine) dipeptide. 8. The artificial tissue of claim 1, wherein said end-capping modified peptide has the general Formula I: R1-[A1]-[A2]-R2 Formula Iwherein:A1 and A2 are each an aromatic amino acid residue and are the same;R1 is selected from the group consisting of N-terminus amine and an N-terminus end-capping moiety; andR2 is elected from the group consisting of C-terminus carboxylic acid and a C-terminus end-capping moiety, provided that at least one of R1 and R2 is an end capping moiety. 9. A matrix made of at least one nanostructure, said at least one nanostructure being selected from the group consisting of a tubular nanostructure and a fibrillar nanostructure, and comprising a plurality of aromatic homodipeptides, wherein at least one of said homodipeptides is an end-capping modified peptide, the matrix being capable of introducing and growing therethrough cells. 10. The matrix of claim 9, wherein said end-capping modified peptide comprises an aromatic end capping moiety. 11. The matrix of claim 10, wherein said aromatic end-capping moiety is selected from the group consisting of 9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz). 12. The matrix of claim 9, wherein said homodipeptide is phenylalanine-phenylalanine dipeptide.
Berger Dieter (Viernheim DEX) Frey Gnter (Ludwigshafen DEX) Kuhr Manfred (Mannheim DEX) Werner Wolfgang (Mannheim DEX), Diagnostic agents for the detection of leukocytes in body fluids.
Pollak Alfred (Toronto CAX) Kirby Robert A. (Acton CAX) Dunn-Dufault Robert (Bramalea CAX), Hydrazino-type radionuclide chelators having an N3S configuration.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Palmer David C. ; Abdel-Magid Ahmed ; Breslav Michael S. ; Eggmann Urs P.,CHX ; Harris Bruce ; Haslego Mark L. ; Sorgi Kirk L., Liquid phase process for the preparation of GnRH peptides.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Findeis Mark A. ; Gefter Malcolm L. ; Musso Gary ; Signer Ethan R. ; Wakefield James ; Molineaux Susan ; Chin Joseph ; Lee Jung-Ja ; Kelley Michael ; Komar-Panicucci Sonja ; Arico-Muendel Christopher, Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids.
Afroditi Kapurniotu DE; Jurgen Bernhagen DE; Herwig Brunner DE, Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies.
Fischer Andreas (Bonn DEX) Schwarz Alexander (Rehovot ILX) Wandrey Christian (Juelich DEX) Knaup Guenter (Bruchkoebel DEX) Bommarius Andreas (Frankfurt DEX) Drauz Karl-Heinz (Freigericht DEX), Process for the enzymatic preparation of protected and unprotected di- and oligopeptides in aqueous solutions.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Zarkoob Shahrzad ; Reneker Darrell H. ; Ertley Dale ; Eby R. K. ; Hudson Steven D., Synthetically spun silk nanofibers and a process for making the same.
Biesecker Greg (Boulder CO) Jayasena Sumedha D. (Boulder CO) Gold Larry (Boulder CO) Smith Drew (Boulder CO) Kirschenheuter Gary P. (Arvada CO), Systematic evolution of ligands by exponential enrichment: blended SELEX.
Burke Donald (Boulder CO) Tarasow Ted (Boulder CO) Eaton Bruce E. (Boulder CO) Gold Larry (Boulder CO), Systematic evolution of ligands by exponential enrichment: chimeric selex.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.